Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198119
Abstract: Modakafusp alfa is a first-in-class immunocytokine directing interferon-α to CD38-positive cells. In our previously reported phase 1/2 trial, the maximum tolerated dose of modakafusp alfa in patients with RRMM was 3 mg/kg every 4 weeks… read more here.
Keywords: 120 cohort; cohort; modakafusp alfa; 240 cohort ... See more keywords